Immune Design Corp. (IMDZ) Trading 8.8% Higher

Immune Design Corp. (NASDAQ:IMDZ) shares traded up 8.8% on Monday . The company traded as high as $4.95 and last traded at $4.95. 911,300 shares were traded during trading, an increase of 220% from the average session volume of 285,005 shares. The stock had previously closed at $4.55.

A number of research analysts recently weighed in on the company. Zacks Investment Research lowered Immune Design Corp. from a “buy” rating to a “hold” rating in a research report on Friday. BidaskClub lowered Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. Royal Bank Of Canada assumed coverage on Immune Design Corp. in a report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 target price for the company. ValuEngine raised Immune Design Corp. from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Finally, Wells Fargo & Company lowered Immune Design Corp. from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $29.00 to $10.00 in a report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $13.19.

Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.11. The firm had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.62 million. Immune Design Corp. had a negative return on equity of 68.69% and a negative net margin of 619.62%. research analysts forecast that Immune Design Corp. will post -1.89 EPS for the current fiscal year.

In related news, major shareholder Leo Guthart bought 10,000 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were bought at an average cost of $9.70 per share, for a total transaction of $97,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Peter Svennilson bought 2,681,000 shares of the stock in a transaction that occurred on Friday, October 27th. The shares were bought at an average price of $4.10 per share, for a total transaction of $10,992,100.00. The disclosure for this purchase can be found here. Insiders have purchased 5,300,000 shares of company stock worth $21,874,900 over the last quarter. 20.70% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in IMDZ. FMR LLC lifted its position in shares of Immune Design Corp. by 0.4% in the first quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock valued at $3,027,000 after acquiring an additional 1,699 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Immune Design Corp. by 18.9% in the first quarter. TIAA CREF Investment Management LLC now owns 45,574 shares of the biotechnology company’s stock valued at $310,000 after acquiring an additional 7,236 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Immune Design Corp. by 170.0% in the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock valued at $760,000 after acquiring an additional 70,351 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Immune Design Corp. by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 8,418 shares in the last quarter. Finally, Personal Capital Advisors Corp purchased a new position in shares of Immune Design Corp. in the second quarter valued at about $356,000. Institutional investors and hedge funds own 51.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/11/13/immune-design-corp-imdz-trading-8-8-higher.html.

About Immune Design Corp.

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply